scholarly journals Lymphoma development and survival in refractory coeliac disease type II: Histological response as prognostic factor

2017 ◽  
Vol 5 (2) ◽  
pp. 208-217 ◽  
Author(s):  
P Nijeboer ◽  
RLJ Wanrooij ◽  
T Gils ◽  
NJ Wierdsma ◽  
GJ Tack ◽  
...  
Gut ◽  
2012 ◽  
Vol 62 (4) ◽  
pp. 509-519 ◽  
Author(s):  
Frederike Schmitz ◽  
Jennifer M L Tjon ◽  
Yuching Lai ◽  
Allan Thompson ◽  
Yvonne Kooy-Winkelaar ◽  
...  

2003 ◽  
Vol 124 (4) ◽  
pp. A16 ◽  
Author(s):  
Marije S. Goerres ◽  
Peter J. Wahab ◽  
Joos A. Kerchkhaert ◽  
Jos W. Meijer ◽  
Vera Mattijssen ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A131-A131 ◽  
Author(s):  
C MULDER ◽  
P WAHAB ◽  
A TAN ◽  
J MEIJER

2001 ◽  
Vol 120 (5) ◽  
pp. A131 ◽  
Author(s):  
Cjj Mulder ◽  
Pj Wahab ◽  
Acitl Tan ◽  
Jwr Meijer

2016 ◽  
Vol 25 (3) ◽  
pp. 385-388 ◽  
Author(s):  
Yvette H. Van Beurden ◽  
Tom Van Gils ◽  
Nienke A. Van Gils ◽  
Zain Kassam ◽  
Chris J.J. Mulder ◽  
...  

Treatment of refractory celiac disease type II (RCD II) and preventing the development of an enteropathy associated T-cell lymphoma in these patients is still difficult. In this case report, we describe a patient with RCD II who received fecal microbiota transfer as treatment for a recurrent Clostridium difficile infection, and remarkably showed a full recovery of duodenal villi and disappearance of celiac symptoms. This case suggests that altering the gut microbiota may hold promise in improving the clinical and histological consequences of celiac disease and/or RCD II. Abbreviations: CDI: Clostridium difficile infection; EATL : enteropathy associated T-cell lymphoma; FMT: fecal microbiota transfer; IEL: intraepithelial lymphocytes; RCD II: refractory celiac disease type II; TPN: total parenteral nutrition.


Sign in / Sign up

Export Citation Format

Share Document